Allergan Gets OK to Market Ocuflox
- Share via
IRVINE — Allergan Inc. said Tuesday that it has received U.S. Food and Drug Administration marketing clearance for its Ocuflox solution. Ocuflox is a topical anti-infective agent for bacteria that cause inflammation of membranes surrounding the eye. The company said it plans to launch Ocuflox in America by the end of the year.
The company said it currently sells the solution in Australia, Brazil, France, Greece, Italy, South Africa and the United Kingdom; approval in Canada and Spain is pending.
The company’s stock rose 12.5 cents Tuesday to close at $22.625 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
